Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 1997

View Archived Issues

Creative BioMolecules: Q1 1997 highlights

CytoTherapeutics: Q1 1997 highlights

Hybridon: Q1 1997 highlights

Flamel Technologies: Report to investors at Alex, Brown Health Care Conference

Cypros: Report to investors at Van Kasper & Co. Growth Stock Conference

Selective M3 antagonists from Banyu

Kyoto describes ACAT/lipid peroxidation inhibitors

Nissan Chem. reveals antiplatelet agents

Hayashibara discloses potent, broad-spectrum antitumor agents

Ono reports AGE inhibitors and antioxidants

Heat shock protein fragments for RA from Peptide Therapeutic

Taisho prepares inhibitors of the production of IL-1beta/IL-6

Activated Cell Therapy's immunotherapy for prostate cancer enters clinic

Alphagan introduced in the U.K.

U.K. introduction for Nasonex

Integrin recognition surface identified

Loxiglumide efficacy in GERD reported

Fujisawa's new agent for hepatic ischemia-reperfusion injury

Bristol-Myers Squibb strengthens R&D in the Czech Republic

Gen-Probe and bioMerieux sign nucleic acid probe diagnostic agreement

Lamivudine clinical results in HBV

Gastric roles of COX-1 and COX-2 debated at DDW

Pasteur Merieux Connaught launches combination vaccine with acellular component

News on gastric ulcer drugs reported at Digestive Disease Week

Vital to develop anticancer drug

NIH sponsors ProScript's research on novel malaria treatment

Oxigene signs agreement for combretastatin development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...